Mesalazin Orion (Mesalazine)

Mesalazine exerts its effect locally in the gut by inhibiting cyclooxygenase and lipoxygenase enzymes. This reduces the production of prostaglandins and leukotrienes, key mediators of inflammation, thereby decreasing mucosal irritation and promoting healing of the intestinal lining.

The specific dose of Mesalazin Orion is determined by the prescribing physician based on the individual patient's disease severity, location, and response to therapy. Dosage regimens are tailored to each patient and should follow the prescriber's instructions.

Safety data for mesalazine in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies if appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Mesalazin Orion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mesalazin Orion belongs to the aminosalicylate class, offering a topical anti‑inflammatory effect within the gut. Compared with systemic immunosuppressants or biologics, it generally has a more favorable safety profile but may be less potent for severe disease. Choice of therapy depends on disease severity, patient tolerance, and treatment goals.

Mesalazin Orion should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability and potency throughout its shelf life.

Mesalazin Orion is taken orally, usually with water. The exact administration schedule—such as once or multiple times daily—depends on the prescriber's instructions and the specific formulation provided.

Serious risks include severe allergic reactions (anaphylaxis), blood disorders like neutropenia, liver enzyme elevations indicating hepatic injury, pancreatitis, and kidney inflammation. Patients should be monitored regularly for these rare but potentially life‑threatening events.

Mesalazin Orion is contraindicated in individuals with a known hypersensitivity to mesalazine or other aminosalicylates. It should also be used with caution in patients with severe renal or hepatic impairment, and it is not recommended for children unless specifically prescribed by a specialist.